ArticleJACC. Case reports2026
Unmasking AL Cardiac Amyloidosis During Familial Cardiomyopathy Screening.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmyloid light-chain (AL) amyloidosis is a life-threatening plasma cell disorder in which prognosis is largely determined by cardiac involvement. Early diagnosis remains uncommon. CASE SUMMARY: A 65-year-old asymptomatic man was referred for familial hypertrophic cardiomyopathy screening. Echocardiography showed severe left ventricular hypertrophy, and cardiac magnetic resonance revealed biventricular hypertrophy with normal extracellular volume, along with late gadolinium enhancement in the interventricular septum and both atria, raising suspicion for infiltrative cardiomyopathy. Bone scintigraphy showed no pathologic cardiac tracer uptake (Perugini grade 0). An abnormal κ/λ ratio prompted hematologic work-up, and endomyocardial biopsy confirmed AL cardiac amyloidosis. Treatment with daratumumab, cyclophosphamide, bortezomib, and dexamethasone was initiated. DISCUSSION: This case highlights the diagnostic value of multimodality imaging and systematic monoclonal protein screening in unexplained ventricular hypertrophy. TAKE-HOME MESSAGE: A high index of suspicion is required to avoid missing early AL cardiac amyloidosis, particularly in patients with unexplained ventricular hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.